Abstract
Sildenafil shows an intense and prolonged inhibitory effect on the smooth muscle cells of corpus cavernosum arterioles by blocking phosphodiesterase type 5 that inactivates the nitric oxide-stimulated cyclic guanosine monophosphate. We investigated if this inhibitory effect is also displayed on smooth muscle cells of the esophagus. In 16 normal subjects (9 men and 7 women, mean age 34 years, range 22–56) esophageal motility was recorded by means of a low-compliance manometric system with side holes for the esophageal body and a sleeve for the lower esophageal sphincter (LES). After a basal period of 60 min, a tablet of sildenafil 50-mg ground and dissolved in water was infused in the stomach in eight subjects (group A) and a placebo tablet in the other eight subjects (group B), randomly and in a double-blind manner; the recording continued for another 60 min. LES tone and postdeglutitive residual pressure, as well as amplitude, propagation velocity, and onset latency of contractions were measured each minute, the values averaged every 5 min, and the mean of the entire basal and postinfusion periods was calculated. The postinfusion values were compared with the basal values in each group and with the corresponding values of the other groups. The percent variations of postinfusion values with respect to basal values were also compared. Sildenafil induced a statistically significant decrease of LES tone, residual pressure, wave amplitude, and propagation velocity and a significant increase of onset latency of pressure waves in comparison with the values of the basal period and placebo. The inhibitory effect reached its maximum 10–15 min after the infusion and lasted about 1 hr. In conclusion, sildenafil markedly inhibits the motor activity of the esophageal musculature by decreasing LES pressure, wave amplitude, and propagation velocity and increasing the onset latency of pressure waves.
Similar content being viewed by others
REFERENCES
Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA: Oral sildenafil in the treatment of erectile dysfunction. New Engl J Med 338:1397–1404, 1998
Boolell M, Allen MJ, Ballard S, Gepi-Attee SG, Muirhead GJ, Naylor AM, Osterloch IH, Gingell C: Sildenafil, an orally active type 5 cyclic GAIP specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 8:47–52, 1996
Moreland RB, Goldstein I, Traish A: Sildenafil, a novel inhibitor of phopshodiesterase type 5 in human corpus cavernosum muscle cells. Life Sci 62:309–318, 1998
Du C, Murray J, Conklin JL: Cyclic GMP mediates nitric oxide produced NANC hyperpolarization of opossum esophageal circular smooth muscle. Gastroenterology 102:443A, 1992
Tottrup MA, Knudsen MA, Madse G, Anderssori KE, Forman A: The role of the L-arginine-nitric oxide pathway for relaxation of the human lower esophageal sphincter. Gastroenterology 102:527A, 1992
Murray JA, Ledlow A, Launspach J, Evans D, Loveday M, Conklin JL: The effects of recombinant human hemoglobin on esophageal motor function in humans. Gastroenterology 109:1241–1248, 1995
Konturek JW, Thor P, Lukaszyk A, Gabryelewicz A, Konturek SJ, Domschke W: Endogenous nitric oxide in the control of esophageal motility in humans. J Physiol Pharmacol 48:201–209, 1997
Anand N, Paterson WG: Nitrix oxide (NO) is the mediator of physiological lower esophageal sphincter relaxation (LESR) in vivo. Gastroenterology102:415A, 1992
Hirsh DP, Holloway RH, Tytgat GN, Boeckxstaens GE: Involvement of nitric oxide in human transient lower esophageal sphincter relaxations and esophageal primary peristalsis. Gastroenterology 115:1374–1380, 1998
Anand N, Paterson WG: Role of nitric oxide in esophageal peristalsis. Am J Physiol 266:G123–131, 1994
Yamato S, Spechler JS, Goyal RK: Role of nitrc oxide in esophageal peristalis in the opossum. Gastroenterology 103:197–204, 1992
Sifrim D, Janssens J, Vantrappen G: A wave of inhibition precedes primary peristaltic contractions in the human esophagus. Gastroenterology 103:876–882, 1992
Weisbrodt NW, Christensen J: Gradients of contractions in the opossum esophagus. Gastroenterology 62:1159–1166, 1972
Janssens J, Sifrim D, Lerut A: Esophageal motility disorders: A pathophysiological concept. Gastroenterology 108:A621, 1995
Bortolotti M, Mari C, Lopilato C, Porrazzo G, Miglioli M: Effects of sildenafil on esophageal motility of patients with idiopathic achalasia. Gastroenterology 118:253–257, 2000
Sifrim D, Janssens J, Vantrappen G: Failing deglutitive inhibition in primary esophageal motility disorders. Gastroenterology 106:875–882, 1994
Pfizer: NDA 20-895. Groton, Connecticut, Pfizer Central Research, 1998
Goldenberger MM: Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction. Clin Ther 20:1033–1048, 1998
Rendell MS: Sildenafil for treatment of erectile dysfunction in men with diabetes. JAMA 281:421–426, 1999
Dodds WJ, Dent J, Hogan WJ, Helm JF, Hauser R, Patel GK, Egide MS: Mechanisms of gastroesophageal reflux in patients with reflux esophagitis. N Engl J Med 307:1547–1552, 1982
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bortolotti, M., Mari, C., Giovannini, M. et al. Effects of Sildenafil on Esophageal Motility of Normal Subjects. Dig Dis Sci 46, 2301–2306 (2001). https://doi.org/10.1023/A:1012383424783
Issue Date:
DOI: https://doi.org/10.1023/A:1012383424783